These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 11692443)
1. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Ragde H; Grado GL; Nadir BS Arch Esp Urol; 2001 Sep; 54(7):739-47. PubMed ID: 11692443 [TBL] [Abstract][Full Text] [Related]
2. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Ragde H; Korb LJ; Elgamal AA; Grado GL; Nadir BS Cancer; 2000 Jul; 89(1):135-41. PubMed ID: 10897010 [TBL] [Abstract][Full Text] [Related]
3. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy. Potters L; Cha C; Oshinsky G; Venkatraman E; Zelefsky M; Leibel S Cancer J Sci Am; 1999; 5(5):301-6. PubMed ID: 10526671 [TBL] [Abstract][Full Text] [Related]
5. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591 [TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants. Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460 [TBL] [Abstract][Full Text] [Related]
7. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244 [TBL] [Abstract][Full Text] [Related]
9. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience. Henry AM; Al-Qaisieh B; Gould K; Bownes P; Smith J; Carey B; Bottomley D; Ash D Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):50-6. PubMed ID: 20005453 [TBL] [Abstract][Full Text] [Related]
10. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332 [TBL] [Abstract][Full Text] [Related]
11. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy. Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612 [TBL] [Abstract][Full Text] [Related]
13. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961 [TBL] [Abstract][Full Text] [Related]
14. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation. Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527 [TBL] [Abstract][Full Text] [Related]
15. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452 [TBL] [Abstract][Full Text] [Related]
16. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. Potters L; Morgenstern C; Calugaru E; Fearn P; Jassal A; Presser J; Mullen E J Urol; 2005 May; 173(5):1562-6. PubMed ID: 15821486 [TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Dattoli M; Wallner K; True L; Cash J; Sorace R Cancer; 2007 Aug; 110(3):551-5. PubMed ID: 17577217 [TBL] [Abstract][Full Text] [Related]
18. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279 [TBL] [Abstract][Full Text] [Related]
19. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788 [TBL] [Abstract][Full Text] [Related]
20. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]